PAR.AX Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 09:10):

Paradigm Biopharmaceuticals Limited, a drug repurposing company, engages in the research and development of therapeutic products for human use in Australia...

Stats
Dzisiejszy wolumen	455 715
Średni wolumen	654 560
Kapitalizacja rynkowa	94.76M
EPS	$0 ( 2024-02-29 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.170
ATR14	$0.00100 (0.37%)

Wolumen Korelacja

Długi: 0.09 (neutral)

Krótki: 0.91 (very strong)

Signal:(41.027) Expect same movement, but be aware

Paradigm Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Paradigm Korelacja - Waluta/Towar

0.86
( strong )

0.00
( neutral )

-0.04
( neutral )

Paradigm Finanse

Annual	2023
Przychody:	$46 760.00
Zysk brutto:	$-125 723 (-268.87 %)
EPS:	$-0.180

FY	2023
Przychody:	$46 760.00
Zysk brutto:	$-125 723 (-268.87 %)
EPS:	$-0.180

FY	2022
Przychody:	$79 224.00
Zysk brutto:	$-257 777 (-325.38 %)
EPS:	$-0.160

FY	2021
Przychody:	$20 550.00
Zysk brutto:	$-78 588.00 (-382.42 %)
EPS:	$-0.171

Financial Reports:

No articles found.

Paradigm

Paradigm Biopharmaceuticals Limited, a drug repurposing company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.